9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats

Epilepsia

Volumn 51, Issue 8, 2010, Pages 1522-1532

  Hill, Andrew J ^a   Weston, Samantha E ^a   Jones, Nicholas A ^a   Smith, Imogen ^a   Bevan, Sarah A ^a   Williamson, Elizabeth M ^a   Stephens, Gary J ^a   Williams, Claire M ^a   Whalley, Benjamin J ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Anticonvulsant; Cannabinoid; Epilepsy; Pentylenetetrazole; Piriform cortex

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; DELTA9 TETRAHYDROCANNABIVARIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MAGNESIUM ION; PENTETRAZOLE; RIMONABANT; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PHOSPHORUS; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABIVARIN 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPILEPTIC DISCHARGE; FEMALE; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; EPILEPSY; EVOKED RESPONSE; FINANCIAL MANAGEMENT; IN VITRO STUDY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CEREBRAL CORTEX; COMPETITIVE BIDDING; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EPILEPSY; EVOKED POTENTIALS; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; PENTYLENETETRAZOLE; PHOSPHORUS ISOTOPES; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 77955327987     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02523.x     Document Type: Article

References (67)

1. Alger BE, Pitler TA, Wagner JJ, Martin LA, Morishita W, Kirov SA, Lenz RA 1996) Retrograde signalling in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells. J Physiol 496 (Pt 1):197 209.
2. Alger BE 2004) Endocannabinoids and their implications for epilepsy. Epilepsy Curr 4:169 173.
3. Ashton CH 2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101 106.
4. Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, Dehpour AR 2008) The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res 81:44 51.
5. Barkai E, Hasselmo MH 1997) Acetylcholine and associative memory in the piriform cortex. Mol Neurobiol 15:17 29.
6. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R 1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23 31.
7. Bernard C, Milh M, Morozov YM, Ben-Ari Y, Freund TF, Gozlan H 2005) Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci U S A 102:9388 9393.
8. Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ 2006) Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther 317:1072 1078.
9. Blair RE, Deshpande LS, Holbert Ii WH, Churn SB, DeLorenzo RJ 2009) Age-dependent mortality in the pilocarpine model of status epilepticus. Neurosci Lett 453:233 237.
10. Brown SP, Safo PK, Regehr WG 2004) Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24:5623 5631.
11. Brust JC, Ng SK, Hauser AW, Susser M 1992) Marijuana use and the risk of new onset seizures. Trans Am Clin Climatol Assoc 103:176 181.
12. Chiu P, Olsen DM, Borys HK, Karler R, Turkanis SA 1979) The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 20:365 375.
13. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF 2003) Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23:3916 3923.
14. Colasanti BK, Lindamood C III., Craig CR 1982) Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. Pharmacol Biochem Behav 16:573 578.
15. Compton DR, Aceto MD, Lowe J, Martin BR 1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586 594.
16. Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R 1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83:293 298.
17. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R 1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175 185.
18. 35S]GTPS binding in mouse brain cerebellum and piriform cortex membranes. Br J Pharmacol 154:1349 1358.
19. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ 2007a) Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol 558:52 59.
20. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ 2007b) Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett 411:11 16.
21. Di Marzo V 2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438 455.
22. Ebert U, Wlaz P, Loscher W 2000) High susceptibility of the anterior and posterior piriform cortex to induction of convulsions by bicuculline. Eur J Neurosci 12:4195 4205.
23. Echegoyen J, Armstrong C, Morgan RJ, Soltesz I 2009) Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res 85:123 127.
24. Egert U, Heck D, Aertsen A 2002a) Two-dimensional monitoring of spiking networks in acute brain slices. Exp Brain Res 142:268 274.
25. Egert U, Knott T, Schwarz C, Nawrot M, Brandt A, Rotter S, Diesmann M 2002b) MEA-Tools: an open source toolbox for the analysis of multi-electrode data with MATLAB. J Neurosci Methods 117:33 42.
26. Falenski KW, Carter DS, Harrison AJ, Martin BR, Blair RE, DeLorenzo RJ 2009) Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res 1262:64 72.
27. Farrimond JA, Hill AJ, Jones NA, Stephens GJ, Whalley BJ, Williams CM 2009) A cost-effective high-throughput digital system for observation and acquisition of animal behavioral data. Behav Res Methods 41:446 451.
28. Fish BS, Consroe P, Fox RR 1983) Convulsant-anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits. Behav Genet 13:205 211.
29. Gill EW, Paton WD, Pertwee RG 1970) Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 228:134 136.
30. Gordon E, Devinsky O 2001) Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 42:1266 1272.
31. Gross DW, Hamm J, Ashworth NL, Quigley D 2004) Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 62:2095 2097.
32. Haberly LB 1985) Neuronal circuitry in olfactory cortex: anatomy and functional implications. Chemical Sense 10:219 238.
33. Hansen HH, Azcoitia I, Pons S, Romero J, García-Segura LM, Ramos JA, Hansen HS, Fernández-Ruiz J 2002) Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 82:154 158.
34. Hasselmo ME, Wilson MA, Anderson BP, Bower JM 1990) Associative memory function in piriform (olfactory) cortex: computational modeling and neuropharmacology. Cold Spring Harb Symp Quant Biol 55:599 610.
35. Jones NA, Hill AJ, Smith I, Bevan S, William CM, Whalley BJ, Stephens GJ 2010) Cannabidiol displays anti-epileptiform and anti-seizure properties in vitro and in vivo. J Pharmacol Exp Ther 332:569 577.
36. Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA 2007) Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 322:1059 1066.
37. Karler R, Cely W, Turkanis SA 1974) Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids. Life Sci 15:931 947.
38. Kozan R, Ayyildiz M, Agar E 2009) The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 50:1760 1767.
39. Loscher W, Ebert U 1996) The role of the piriform cortex in kindling. Prog Neurobiol 50:427 481.
40. Ludanyi A, Eross L, Czirjak S, Vajda J, Halasz P, Watanabe M, Palkovits M, Magloczky Z, Freund TF, Katona I 2008) Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci 28:2976 2990.
41. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ 2006) Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 547:65 74.
42. Lutz B 2004) On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 68:1691 1698.
43. Ma YL, Weston SE, Whalley BJ, Stephens GJ 2008) The phytocannabinoid [Delta]9-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol 154:204 215.
44. Mason R, Cheer JF 2009) Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus. Front Integr Neurosci 3:13.
45. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave K, During M, Klugmann M, Wölfel B, Dodt H, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B 2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51:455 466.
46. Naderi N, Aziz Ahari F, Shafaghi B, Najarkolaei AH, Motamedi F 2008) Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm 115:1501 1511.
47. Olsen RW 1981) The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol Cell Biochem 39:261 279.
48. Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK 2007) The psychoactive plant cannabinoid, [Delta]9-tetrahydrocannabinol, is antagonized by [Delta]8- and [Delta]9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150:586 594.
49. Pertwee RG 2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: [Delta]9-tetrahydrocannabinol, cannabidiol and [Delta]9-tetrahydrocannabivarin. Br J Pharmacol 153:199 215.
50. Piazza PV, Lafontan M, Girard J 2007) Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. Diabetes Metab 33:97 107.
51. Pohl M, Mares P 1987) Effects of flunarizine on Metrazol-induced seizures in developing rats. Epilepsy Res 1:302 305.
52. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A 2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12:1152 1158.
53. Rizzo V, Ferraro G, Carletti F, Lonobile G, Cannizzaro C, Sardo P 2009) Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci Lett 462:135 139.
54. Rubino T, Parolaro D 2008) Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286:S108 S113.
55. Shafaroodi H, Samini M, Moezi L, Homayoun H, Sadeghipour H, Tavakoli S, Hajrasouliha AR, Dehpour AR 2004) The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 47:390 400.
56. Shen M, Thayer SA 1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8 13.
57. Steffens M, Schulze-Bonhage A, Surges R, Feuerstein TJ 2005) Fatty acid amidohydrolase in human neocortex - activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci Lett 385:13 17.
58. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG 2005) Evidence that the plant cannabinoid [Delta]9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146:917 926.
59. Turkanis SA, Karler R 1981) Electrophysiologic properties of the cannabinoids. J Clin Pharmacol 21:449S 463S.
60. Vitalis T, Lainé J, Simon A, Roland A, Leterrier C, Lenkei Z 2008) The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci 28:1705 1718.
61. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ 2001) Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 428:51 57.
62. Wallace MJ, Martin BR, DeLorenzo RJ 2002) Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295 301.
63. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ 2003) The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307:129 137.
64. 2+- free media-induced status epilepticus in transverse piriform cortical slices, in vitro. Proceedings of the British Pharmacological Society. BPS Winter Meeting, Winter 2007. Brighton.
65. Whalley BJ, Postlethwaite M, Constanti A 2005) Further characterization of muscarinic agonist-induced epileptiform bursting activity in immature rat piriform cortex, in vitro. Neuroscience 134:549 566.
66. Whalley BJ, Stephens GJ, Constanti A 2009) Investigation of the effects of the novel anticonvulsant compound carisbamate (RWJ-333369) on rat piriform cortical neurones in vitro. Br J Pharmacol 156:994 1008.
67. Zhao Q, Holmes GL 2006) Repetitive seizures in the immature brain. In Pitkanen A, Schwartzkroin PA, Moshe SL (Eds) Models of seizures and epilepsy. Elsevier Academic Press, San Diego, pp. 341 350.